Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
ApexOnco Front Page
Recent articles
Adverse events will be closely watched when full data are reported.
Any hopes of differentiation could come down to side effects.
Early data on SSGJ-707 in PD-L1-positive lung cancer spur comparisons against ivonescimab.
DZD8586 shows some evidence that it can rescue BTK failures, but its precise role remains unclear.
BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.
In first-line renal cancer, zanzalintinib plus Opdivo has outshone Cabometyx plus Opdivo.
The Breakwater study hits on overall survival with "unprecedented" data.
